Articles tagged with Cancer Medication
A new study by Michigan Medicine found that the Inflation Reduction Act's limit on Medicare Part D spending leads to significant savings for cancer patients prescribed oral chemotherapy. The average annual cost for these medications decreased from $11,284 in 2023 to $3,927 in 2024, resulting in median cost savings of $7,260.
Researchers at UCSF develop a method to target GTPases, enzymes involved in Parkinson's and many other diseases, by using drugs targeting the K-Ras oncogene. This approach reveals new drug binding sites that could not be predicted by computational tools.
A 23-year-old patient with severe systemic lupus erythematosus achieved complete symptom relief after five injections of teclistamab, a cancer medication. The treatment significantly improved kidney function, blood levels, and reduced inflammation in the skin and joints.
Researchers discovered that low-oxygen environments play a crucial role in driving pancreatic cancer cell transformation into aggressive types. Disabling specific genes and using EZH2 inhibitors can reverse this process, suggesting new treatment possibilities for the disease.
Scientists at Van Andel Institute and Icahn School of Medicine have developed a potent anti-cancer compound that inhibits cancer cell growth in MLL-rearranged leukemia. MS-41 effectively targets and degrades ENL, a protein essential to the progression of leukemia cells.
Researchers have developed a novel, more selective inhibitor of the human immunoproteasome using a bacterially derived natural product. The new compound targets autoimmune diseases without disrupting other cellular mechanisms.
Researchers have identified certain times of the day when cancer cells are most responsive to medication-based treatments, suggesting personalized treatment plans could improve efficacy and reduce side effects. The study used a method called high-throughput deep phenotyping to analyze the circadian rhythms of breast cancer cell lines.
A phase II clinical trial found that olaparib, a precision oncology drug, can induce durable complete remissions in recurrent prostate cancer patients with BRCA2 mutations. The study showed that 13 participants, including all 11 with BRCA2 mutations, had a decrease in PSA of at least 50% after treatment.
A computational model can predict which drugs will be most effective in treating diseases caused by mutations that bring protein synthesis to a halt. The predictive model, RTDetective, accelerates the design, development, and efficacy of clinical trials for genetic disorders and cancers.
A new study published in Nature Medicine shows that precision therapy can improve survival for men with metastatic castration-resistant prostate cancer. The treatment, which involves analyzing the genetic profile of the tumor, has been shown to be more effective than chemotherapy in patients whose tumors have specific mutations.
The Ontario Institute for Cancer Research is providing nearly $6 million to eight research teams across Ontario, supporting studies that aim to diagnose and treat cancers more effectively. The Clinical Translational Pathway program will advance new discoveries and bring them to the healthcare system.
Scientists discovered a way to kill pancreatic cancer in mice by combining a ketogenic diet with an existing cancer drug. The diet blocks the cancer's only source of fuel, allowing the drug to take effect and shrink tumors. This finding opens a new vulnerability for treating cancer with diet and personalized therapies.
Researchers highlight the need to develop new anti-angiogenic agents to improve cancer treatment efficacy, citing knowledge gaps in human clinical trials. The review recommends considering tumor mutations, microenvironment, and patient profiles to select optimal AAD combinations.
A trial at UT Health San Antonio found that Sacituzumab Govitecan was well-tolerated and showed signs of effectiveness for patients with breast cancer who had progressed to brain tumors. The drug has been shown to deliver a topoisomerase inhibitor into tumors, providing promising clinical signals of efficacy.
A new editorial published in Aging suggests that starting targeted cancer therapies with high concentrations may slow down the selection for resistance. This approach could potentially be used as a preemptive measure to minimize the development of resistance.
A recent study published in CANCER found that patients with metastatic non–small cell lung cancer treated with immunotherapy had improved overall and cancer-specific survival rates compared to those without it. The median overall survival was eight months, while cancer-specific survival was 10 months.
A study of non-statin cholesterol-lowering medications found that cholesterol absorption inhibitors were associated with a 31% lower odds of liver cancer risk. Statin use was also linked with a 35% lower risk. Fibrates, omega-3 fatty acids, and niacin showed no association.
Researchers developed a new approach to combat cancer by hyperactivating tumor cells, making them stressed and vulnerable to specific drugs. The combination strategy showed promising results in colorectal and pancreatic adenocarcinoma models, paving the way for potential treatment options.
A recent study published in the Journal of Clinical Oncology found that combining different chemotherapy drugs improves testicular cancer's treatability and often curability, even after first-line treatment fails. The study showed a nearly 80% response rate and no significant drop-off in survival over 10 years.
A novel strategy using venetoclax and azacitidine demonstrates significant anti-cancer effect with mild toxicity for relapsed/refractory AML patients. The treatment showed markedly better survival rates after one year compared to a control group, with improved 'graft-versus-leukemia effects' via alterations of immune cells.
Researchers have developed a new technique called burst sine wave electroporation (B-SWE) that can disrupt the blood-brain barrier around brain tumors without causing significant damage to healthy tissue. This method shows promise for treating aggressive brain cancers like glioblastoma, which currently have limited treatment options.
Researchers at Tufts University have identified the immune cells driving cardiac inflammation in cancer patients taking doxorubicin, a commonly used chemotherapy drug. Blocking these cells could potentially prevent cardiac damage and make treatment safer for patients.
A new study published in JAMA Network Open found that hormone modulating therapy (HMT) used to treat breast cancer was associated with a 7% lower risk of developing Alzheimer's disease and related dementias. The protective effect of HMT decreased with age, particularly for women over 80.
Researchers discuss the use of antibody-drug conjugates (ADCs) in treating biologically aggressive tumors, such as uterine serous carcinoma. The ADC T-DXd has shown remarkable preclinical activity against primary USC cells lines and xenografts overexpressing HER2/neu.
Researchers at the University of Plymouth have discovered that administering a HDAC6 inhibitor prior to radiotherapy can inhibit cellular growth and increase cell death in meningioma samples. This promising approach could lead to improved treatment outcomes for malignant meningioma patients.
Researchers at Linköping University created a tool to predict risk of persistent side effects in breast cancer patients treated with taxane drugs. The model uses genetic characteristics to forecast the risk of nerve damage, which can be used to adapt treatment and improve patient outcomes.
Pharmacogenomics (PGx) testing can predict how patients will respond to systemic therapies, enabling personalized treatment plans and optimizing medication dosages. A specific gene variant, HSD3B1, has been linked to castration-resistant prostate cancer progression.
The University of Texas at Arlington's Junha Jeon is developing transition metal-free cross-coupling technologies using arynes to deliver medications safely and effectively. This project aims to improve the production of drugs, particularly for cancer treatment, by reducing impurities left behind by metals.
Researchers describe a new concept for an immune response against cancer and aging using senescent cell-derived vaccines. The vaccines aim to stimulate the immune system against cancer cells and slow down or reverse aging-related diseases.
A study published in JAMA Internal Medicine found that specific exercise concomitant with chemotherapy can prevent nerve damage in many cases. The exercises reduced the incidence of CIPN (chemotherapy-induced peripheral neuropathy) by 50-70% and improved patients' perceived quality of life.
Researchers at CeMM have identified a synthetic variant inspired by the Withanolides group that acts highly specifically against leukemia cells. The molecule disrupts the cholesterol metabolism of tumor cells.
Researchers at Purdue University have developed a patent-pending compound called HSN748 to treat drug-resistant acute myeloid leukemia (AML). The compound has been validated in tests with IU School of Medicine and demonstrated 100% survivability after 120 days. AML is a cancer that begins in bone marrow and can be difficult to treat du...
Researchers at Linköping University and the Medical University of Graz have developed a new cancer treatment using an iontronic pump to deliver continuous, low-dose chemotherapy directly to brain tumors. This approach significantly reduces tumor growth by bypassing the blood-brain barrier, a common obstacle to effective treatment.
Finnish researchers found that blocking the DUSP6 protein can significantly improve treatment outcomes in experimental models by preventing dormant breast cancer cells from waking up. This discovery provides new insights into breast cancer recurrence and offers a potential basis for effective combination therapy.
A new trial indicates that immunotherapy could successfully treat the most common form of colorectal cancer. The study, published in Nature Medicine, found that botensilimab and balstilimab caused tumours to shrink or remain stable in 61% of patients with microsatellite stable metastatic colorectal cancer.
Researchers at Brigham and Women's Hospital have developed a new nanomedicine therapy that delivers anticancer drugs to lung cancer cells and enhances the immune system's ability to fight cancer. The therapy shows promising results in cancer cells in the lab and in mouse lung tumor models, with potential applications for improving care...
A comprehensive molecular portrait of KRAS has been established, revealing its key role in pancreatic cancer progression and resistance to treatment. The study identifies ERK as a critical regulator of KRAS activity, with implications for developing targeted therapies.
The University of Oklahoma has been awarded a $1.2 million grant to lead a Phase 1B clinical trial for the treatment of prostate cancer when it begins to spread beyond the prostate. The trial combines two existing drugs, relugolix and enzalutamide, which may provide more effective treatments for aggressive prostate cancer patients.
A Phase III trial led by the University of Texas M. D. Anderson Cancer Center found proton therapy to be non-inferior to traditional radiation therapy in treating head and neck cancer. The study revealed a significant reduction in malnutrition and feeding-tube dependency with proton therapy.
A study led by Washington State University scientists found that inhibiting CDK7 could help prevent heart damage associated with doxorubicin, a commonly used cancer chemotherapy medication. The researchers also discovered that CDK7 inhibition enhances the medication's cancer-killing capability.
A new study by ECOG-ACRIN Cancer Research Group aimed to address disparities in breast cancer care for Black patients. The trial found that tailoring research to the needs of underserved groups is effective, with docetaxel showing lower rates of peripheral neuropathy and dose reductions compared to paclitaxel.
Pharmaceutical genomic testing can optimize drug dosages and minimize adverse events in treating metastatic prostate cancer. By understanding an individual's genetic variations, clinicians can tailor treatments more effectively.
A study by Sylvester Comprehensive Cancer Center found that durvalumab, a targeted immunotherapy for lung cancer, exceeded official cost-effectiveness thresholds in four countries: the US, Brazil, Singapore, and Spain. The drug's high cost-effectiveness ratio was due to its extended lifespan and quality-of-life benefits.
A study found that moderate-to-vigorous exercise bouts increased natural killer cells' ability to kill cancer cells and made them more susceptible to antibody therapy. This could hold promise for improving treatment outcomes for some forms of chronic lymphocytic leukemia. Further research is needed to confirm these findings.
A novel therapy has been developed to reprogram macrophage immune cells, shifting their balance toward antitumor activity. The treatment, JHU083, blocks the use of glutamine in tumors, reducing growth and triggering cell death. It also boosts immune-activating macrophages, recruiting tumor-killing T-cells and natural killer cells.
Researchers found no significant 'participation effect' in cancer trials, contrary to common belief among patients and healthcare providers. The study's results provide reassurance that not enrolling in a trial doesn't disadvantage a patient's survival outcomes.
A new study published in Nature Biomedical Engineering shows that targeted cancer treatment using antibody-displaying extracellular vesicles reduces tumour growth and improves survival in mice. The treatment has the potential to be used against other diseases and cancer types, offering a more effective and fewer side effects compared t...
A team of POSTECH and ImmunoBiome has discovered a dietary-derived bacterial strain, IMB001, that induces nutritional immunity and boosts anti-tumor responses. The strain works by skewing tumor-infiltrating macrophages toward an inflammatory phenotype, leading to increased cell death of rapidly multiplying tumor cells.
The ECOG-ACRIN Cancer Research Group has launched the ComboMATCH-E5 trial, evaluating the combination of sotorasib and panitumumab in patients with KRAS G12C-mutated advanced solid tumors. The study aims to assess the efficacy and safety of the combination in this patient population.
Researchers at UC San Diego developed a machine learning algorithm to simulate chemistry in drug discovery, synthesizing 32 potential multi-target cancer drugs. The new AI platform, POLYGON, can identify molecules with multiple targets, potentially delivering more effective treatments with fewer side effects.
Researchers have discovered a repurposed cancer drug that can convert acinar cells into insulin-producing cells, which could provide a new avenue for treating diabetes. The treatment partially improved hyperglycemia and persisted without additional treatment in diabetic mice and non-human primates.
A new study from MIT researchers has found that many genes involved in drug metabolism follow a circadian rhythm, affecting how much of a drug is available and how effectively the body breaks it down. The study's findings have implications for developing better dosing schedules for existing drugs.
Researchers at CeMM and Pfizer have developed a novel method to measure the binding activity of hundreds of small molecules against thousands of human proteins. The study revealed tens of thousands of ligand-protein interactions that can now be explored for drug development.
MIT engineers have developed a closed-loop drug-delivery system that can improve chemotherapy outcomes by continuously monitoring patients and adjusting dosage. The new system, called CLAUDIA, uses commercially available equipment to analyze blood samples every five minutes and adjust infusion rates in real-time.
The FDA has approved the use of N-803, an immunotherapy drug, in combination with BCG for treating patients with non-muscle invasive bladder cancer who did not respond to conventional treatment. The approval is based on a trial led by UCLA's Dr. Karim Chamie, which showed improved outcomes and longer overall survival rates.
A new AI-based approach, PERCEPTION, uses single-cell transcriptomics to predict patient response to cancer drugs and monitor resistance. The approach was validated in three clinical trials for multiple myeloma, breast, and lung cancer, with promising results.
Scientists at CNIC have identified mechanisms by which anthracyclines damage the hearts of cancer patients, leading to cardiac injury. The study suggests that a protein-enriched diet may prevent muscle atrophy caused by anthracycline chemotherapy.
Researchers have developed a new treatment that uses tailored doses of anti-cancer drugs released directly into the surgical cavity to treat liver cancer. The approach has shown promise in reducing recurrence rates and minimizing chemotherapy side effects, with potential applications for other types of cancer.
A study reveals that melanomas can 'break' parts of their BRAF gene through genomic deletions, creating alternative versions that resist targeted therapy. This discovery opens new avenues for developing effective treatments for patients with BRAF mutations.
The NCCN 2024 Annual Conference shared updates on improving cancer care worldwide, including plenary sessions on drug shortages and hereditary cancer risk. Key takeaways include the need for transparency around oncology supply chains and the importance of genetic testing to reduce cancer risk.